Antiviral activity, dose–response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial

✍ Scribed by Michiko Shindo; Kazuaki Chayama; Satoshi Mochida; Joji Toyota; Eiichi Tomita; Hiromitsu Kumada; Osamu Yokosuka; Michio Sata; Norio Hayashi; Kazuyuki Suzuki; Takeshi Okanoue; Hirohito Tsubouchi; Hiroki Ishikawa; Taku Seriu; Masao Omata

• Publisher: Springer-Verlag
• Year: 2009
• Tongue: English
• Weight: 242 KB
• Volume: 3
• Category: Article
• ISSN: 1936-0533
• DOI: 10.1007/s12072-009-9135-0